Literature DB >> 20038214

Enhanced delivery of adenovirus, using proteoliposomes containing wildtype or V156K apolipoprotein A-I and dimyristoylphosphatidylcholine.

Ki-Hoon Park1, Chae-Ok Yun, Oh-Joon Kwon, Cheol-Hee Kim, Jae-Ryong Kim, Kyung-Hyun Cho.   

Abstract

The delivery of genes or viruses via liposomes is a common approach used to enhance delivery efficiency. In the current study, to enhance delivery efficiency, proteoliposomes (PLs) containing adenovirus (Ad) were synthesized with dimyristoylphosphatidylcholine (DMPC), cholesterol, and apolipoprotein A-I (apoA-I). Wildtype apoA-I (WT) or V156K-apoA-I (V156K) was then used as an apolipoprotein to compare the structural and functional differences of the PLs. The particle diameter of V156K-PL-Ad was slightly larger than that of WT-PL-Ad, based on native gel electrophoresis. V156K showed more rapid phospholipid bilayer formation than did the WT, based on DMPC clearance. In addition, V156K exhibited maximal fluorescence that was more blue than that of WT in the PL state. Moreover, isothermal denaturation in response to the addition of guanidine hydrochloride (Gnd-HCl) revealed that V156K was more resistant, with no denaturation until 3 M Gnd-HCl was added. In addition, electron microscopy revealed that the viral particles were well associated with PL particles, which had a discoidal structure and were shaped like rouleaux. In addition, treatment of Ad in the PL state showed enhanced green fluorescent protein (GFP) expression when compared with treatment with Ad alone or with DMPC-Ad in hepatoma and brain glioma cells. Cells treated with WT-PL-Ad and V156K-PL-Ad showed approximately 50% more GFP expression than cells treated with Ad alone or with DMPC-Ad after 24 hr of incubation at 37 degrees C, indicating that viral stability was highly increased in the PL state. Furthermore, V156K-PL-Ad showed the highest expression of GFP in adult zebrafish (9 weeks old) at 5 days postinjection (10.5- and 3.8-fold more GFP expressed than by Ad only and DMPC-Ad, respectively). In conclusion, the efficiency of viral delivery and the stability of the virus were significantly enhanced when PLs containing apoA-I were used in cellular and zebrafish models.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20038214     DOI: 10.1089/hum.2008.207

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  6 in total

1.  Modified apolipoprotein (apo) A-I by artificial sweetener causes severe premature cellular senescence and atherosclerosis with impairment of functional and structural properties of apoA-I in lipid-free and lipid-bound state.

Authors:  Wookju Jang; Nam Ho Jeoung; Kyung-Hyun Cho
Journal:  Mol Cells       Date:  2011-04-21       Impact factor: 5.034

2.  Bioreducible crosslinked polyelectrolyte complexes for MMP-2 siRNA delivery into human vascular smooth muscle cells.

Authors:  Dokyoung Lee; Dongkyu Kim; Hyejung Mok; Ji Hoon Jeong; Donghoon Choi; Sun Hwa Kim
Journal:  Pharm Res       Date:  2012-04-04       Impact factor: 4.200

3.  Rapamycin in lipoproteins for enhanced delivery.

Authors:  Kyung-Hyun Cho
Journal:  Cell Cycle       Date:  2012-11-16       Impact factor: 4.534

4.  A proteoliposome containing apolipoprotein A-I mutant (V156K) enhances rapid tumor regression activity of human origin oncolytic adenovirus in tumor-bearing zebrafish and mice.

Authors:  Juyi Seo; Chae-Ok Yun; Oh-Joon Kwon; Eun-Jin Choi; Jae-Young Song; Inho Choi; Kyung-Hyun Cho
Journal:  Mol Cells       Date:  2012-07-30       Impact factor: 5.034

5.  Sterically stabilized recombined HDL composed of modified apolipoprotein A-I for efficient targeting toward glioma cells.

Authors:  Jin Li; Mengmeng Han; Jianfei Li; Zhiming Ge; Qianqian Wang; Kai Zhou; Xiaoxing Yin
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

Review 6.  Reconfiguring Nature's Cholesterol Accepting Lipoproteins as Nanoparticle Platforms for Transport and Delivery of Therapeutic and Imaging Agents.

Authors:  Skylar T Chuang; Siobanth Cruz; Vasanthy Narayanaswami
Journal:  Nanomaterials (Basel)       Date:  2020-05-08       Impact factor: 5.076

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.